Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study.
Alessandra OlivaL LiguoriS CovinoF PetrucciF Cogliati-DezzaA CurtoloG SavelloniM ComiF SaccoG CeccarelliA ViscidoF AlessandriG RaponiF PuglieseC M MastroianniM VendittiPublished in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2024)
CFDC could represent an effective and safe treatment option for CRAB BSI, especially in patients with bacteremic HAP/VAP and frail patients where the risk of acute renal failure during therapy should be avoided.
Keyphrases
- acinetobacter baumannii
- multidrug resistant
- sars cov
- coronavirus disease
- ejection fraction
- randomized controlled trial
- newly diagnosed
- pseudomonas aeruginosa
- systematic review
- liver failure
- prognostic factors
- combination therapy
- chronic kidney disease
- cystic fibrosis
- drug induced
- patient reported outcomes
- patient reported